Lp(a) Testing: Prevalence and Strategies to Improve Uptake

Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its commonality within health plans, and how payers, population health decision makers, and provider groups can integrate Lp(a) testing into broader population health management strategies.

EP: 1.Lp(a) in ASCVD and Guideline Recommendations

EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening

EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing

EP: 10.Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP: 11.Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP: 12.FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP: 13.The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP: 14.Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

Now Viewing

EP: 15.Lp(a) Testing: Prevalence and Strategies to Improve Uptake

Video content above is prompted by the following:

• Currently, how prevalent is Lp(a) testing in the US, both in the overall population and among those with established ASCVD?
• How common is Lp(a) testing within the health plans that you work with?
• How can payers, population health decision makers working at health systems, and provider groups infuse Lp(a) testing into their larger population health management infrastructure?

Related Videos

Related Content

Advertisement

April 24th 2025

Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

Kyle Munz Siddharth M. Patel, MD, MPH

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

April 8th 2025

Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

Kyle Munz Jeremy Wigginton, MD

Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.

May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.

April 2nd 2025

Digital Solutions Can Transform CVD Care, Prevention

Kyle Munz

Mobile self-management programs like that offered by Hello Heart can benefit employers and patients alike as they seek to manage and prevent heart disease.

March 24th 2025

Raising Awareness of Lp(a) to Improve Heart Disease Treatment Approaches

Kyle Munz Nathan Wong, PhD

Lipoprotein(a) [Lp(a)] plays a key role in assessing cardiovascular risk, making awareness efforts equally essential for prevention and early intervention.

Related Content

Advertisement

April 24th 2025

Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

Kyle Munz Siddharth M. Patel, MD, MPH

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

April 8th 2025

Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

Kyle Munz Jeremy Wigginton, MD

Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.

May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.

April 2nd 2025

Digital Solutions Can Transform CVD Care, Prevention

Kyle Munz

Mobile self-management programs like that offered by Hello Heart can benefit employers and patients alike as they seek to manage and prevent heart disease.

March 24th 2025

Raising Awareness of Lp(a) to Improve Heart Disease Treatment Approaches

Kyle Munz Nathan Wong, PhD

Lipoprotein(a) [Lp(a)] plays a key role in assessing cardiovascular risk, making awareness efforts equally essential for prevention and early intervention.